The isoprenaline-induced myocardial infarction model showed reduced infarct size with BPC-157 treatment
Heyman M, Abed J, Lebreton C, Cerf-Bensussan N (2012) Intestinal permeability in coeliac disease: insight into mechanisms and relevance to pathogenesis
Research use only not for human or animal use
BPC-157 was found to be effective in the very low dose range, accelerating wound healing with better granulation tissue formation, re-epithelialisation, dermal remodelling, and higher collagen deposition than the model control group at day 18
[6] Research [edit] BPC-157 was discovered by Predrag Sikiric, a resercher in Zagreb, Croatia who published it in 1993 in Journal of Physiology, Paris